Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q2

4564.TEDINET S100S8MF
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥356m2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥515m2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥695m2023-04-01 → 2023-09-30Cons.Operating income
Operating income−¥618m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income−¥708m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥1.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥644m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥709m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥613m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥711m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥614m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥711m2023-04-01 → 2023-09-30Cons.Profit loss
Net income−¥614m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.2bnat 2023-09-30Cons.Assets
Total assets¥1.5bnat 2023-03-31Cons.Assets
Total assets¥1.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥233mat 2023-09-30Cons.Liabilities
Total liabilities¥656mat 2023-03-31Cons.Liabilities
Net assets / equity¥935mat 2023-09-30Cons.Net assets
Net assets / equity¥855mat 2023-03-31Cons.Net assets
Net assets / equity¥1.3bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥881mat 2023-09-30Cons.Cash and deposits
Cash and deposits¥1.1bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥881mat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.8bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥880m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥795m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥517m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥34m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥20m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥677m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥96m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-3.422023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.452023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.812022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.192022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.742022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio73.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio51.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio76.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥183m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥109m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥537,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥387,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥149,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥403m
—segment totalrevenue2023-04-01 → 2023-09-30¥357m
—segment totalrevenue external2023-04-01 → 2023-09-30¥356m
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥149,000
—segment totalsegment profit2023-04-01 → 2023-09-30−¥512m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥188m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥48m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30−¥382m
—segment totalrevenue2022-04-01 → 2022-09-30¥515m
—segment totalrevenue external2022-04-01 → 2022-09-30¥515m
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥111,000
—segment totalsegment profit2022-04-01 → 2022-09-30−¥430m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 421
ItemContextValueUnit
Net salesCurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember537000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember356064000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember356602000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-149000JPY
Net salesCurrentYTDDuration356452000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember-403450000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember-108528000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember-511979000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-182779000JPY
Operating incomeCurrentYTDDuration-694759000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-11-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第23期第２四半期（自　2023年７月１日　至　2023年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)オンコセラピー・サイエンス株式会社
Company name in english cover pageFilingDateInstantOncoTherapy Science, Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　嶋田　順一
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区東田町１番地２
Telephone number address of registered headquarter cover pageFilingDateInstant044－201－6429
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)管理本部長　水越　潤一
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区東田町１番地２
Telephone number nearest place of contact cover pageFilingDateInstant044－201－6429
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)管理本部長　水越　潤一
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE05363
Fund codeFilingDateInstant－
Security codeFilingDateInstant45640
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコセラピー・サイエンス株式会社
Filer name in englishFilingDateInstantOncoTherapy Science, Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Current fiscal year start dateFilingDateInstant2023-04-01
Current period end dateFilingDateInstant2023-09-30
Type of current periodFilingDateInstantQ2
Current fiscal year end dateFilingDateInstant2024-03-31
Previous fiscal year start dateFilingDateInstant2022-04-01
Comparative period end dateFilingDateInstant2022-09-30
Previous fiscal year end dateFilingDateInstant2023-03-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant－
Report amendment flagFilingDateInstantfalse

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass